Tango Therapeutics, Inc.
TNGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001819133
In the last 90 days, Tango Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 247 institutions reported holding it in 13F filings for Q2 2026, worth $6.60B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Tango Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 2 insiders, $2.34M in total
- Insiders trading
- 2
- Net value
- −$2.34M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Tango Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Newcomb Jessica | Principal Accounting Officer | 59,121 | Sep 24, 2026 | 1 |
| Crystal Adam | President, R&D | 115,743 | Sep 3, 2026 | 11 |
| Azelby Robert | Director | 5,740 | Jun 23, 2026 | 1 |
| Calhoun Lesley Ann | Director | 16,500 | Jun 8, 2026 | 1 |
| Lee Sung | Director | 22,870 | Jun 8, 2026 | 3 |
| Rothenberg Mace | Director | 41,500 | Jun 8, 2026 | 1 |
| Ketchum John B | Director | 24,937 | Jun 8, 2026 | 1 |
| Gall Matthew | Chief Financial Officer | 40,000 | May 5, 2026 | 1 |
| Beckman Daniella | Chief Financial Officer | 184,297 | Feb 4, 2026 | 1 |
| Weber Barbara | Director, Executive Chair | 1,629,254 | Feb 4, 2026 | 1 |
| Peters Malte | President & CEO | 367,500 | Jan 12, 2026 | 2 |
| TRV GP IV, LLC | 10% Owner | 13,386,574 | Oct 27, 2025 | 2 |
| Third Rock Ventures GP IV, L.P. | 10% Owner | 13,386,574 | Oct 27, 2025 | 2 |
| Third Rock Ventures IV, L.P. | 10% Owner | 13,386,574 | Oct 27, 2025 | 2 |
| Borisy Alexis | Director | 17,500 | Jun 9, 2025 | 0 |
| Barry Douglas | General Counsel | 66,014 | Feb 6, 2025 | 0 |
| EcoR1 Capital, LLC | 10% Owner | 10,630,736Indirect | Nov 8, 2024 | 0 |
| Davis Aaron I. | Other: See remarks | 3,610,642Indirect | Nov 7, 2024 | 0 |
| Boxer Capital Management, LLC | Other: See remarks | 3,610,642Indirect | Nov 7, 2024 | 0 |
| MVA Investors, LLC | Other: See remarks | 108,793 | Jul 2, 2024 | 0 |
| Lewis Joseph | Other: See remarks | 8,198,642 | Oct 17, 2023 | 0 |
| Boxer Asset Management Inc. | Other: See remarks | 8,198,642 | Oct 17, 2023 | 0 |
| Boxer Capital, LLC | Other: See remarks | 8,198,642 | Oct 17, 2023 | 0 |
| Huber Reid M | Director | 5,000 | Jun 8, 2023 | 0 |
| Huang Alan | Chief Scientific Officer | 167,584 | Mar 2, 2023 | 0 |
| Weitzman Aaron | Chief Medical Officer | – | Dec 5, 2022 | 0 |
| Rudoltz Marc | Chief Medical Officer | – | Nov 3, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $22.88 | −$617.6K | −18.9%115.7K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)7:23 PM ET | Jul 1 | 1 day | Crystal AdamPresident, R&D | SSale | −27.0K | $29.59 | −$798.9K | −18.9%115.7K after | 2 lots10b5-1 |
| Aug 5, 2026 (view filing)4:01 PM ET | Aug 3 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $27.24 | −$735.5K | −18.9%115.7K after | 2 lots10b5-1 |
| Sep 3, 2026 (view filing)4:01 PM ET | Sep 1 | 2 days | Crystal AdamPresident, R&D | SSale | −27.0K | $22.37 | −$603.9K | −18.9%115.7K after | 10b5-1 |
| Sep 24, 2026 (view filing)7:41 PM ET | Sep 22 | 2 days | Newcomb JessicaPrincipal Accounting Officer | SSale | −8.20K | $24.22 | −$198.6K | −12.2%59.1K after | 3 lots10b5-1 |